Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology e-bog

Biology of EPO,- Classification and characterization of anemia in cancera,- Pathophysiology of cancer-related anemia,- Prevalence, pathophysiology, predictive factors, and prognostic significance of anemia in cancer chemotherapy,- Incidence and impact of anemia in radiation oncology,- Relationship between anemia and tumor hypoxia,- Tumor hypoxia and therapeutic resistance,- Impact of anemia on organ functions,- Relationship between anemia, fatigue, and quality of life in cancer patients,- Red blood cell transfusions, risks and limitations,- Pharmacology, pharmacokinetics and safety of rhEPO,- rhEPO in anemia associated with multiple myeloma and non-Hodgkin lymphoma,- Use of rhEPO in the treatment of myelodysplastic syndromes,- rhEPO in anemia associated with solid tumors and chemotherapy,- Predictive factors for response of anemia to rhEPO,- rhEPO in hematopoietic stem cell mobilization, transplantation, and in-vitro expansion,- Clinical trials using rhEPO in radiation oncology,- rhEPO in pediatric oncology,- rhEPO in surgical oncology,- Erythropoiesis, iron metabolism and iron supplementation during erythropoietin therapy,- Optimal level of hemoglobin in cancer patients,- Protection of metabolic and exercise capacity following treatment with rhEPO,- Effects of treatment with rhEPO on quality of life in anemic cancer patients,- Effect of rhEPO on survival in anemic cancer patients receiving chemotherapy,- Cost-effectiveness of treatment with rhEPO in oncology,- Current status and future developments of rhEPO in clinical oncology,- Subject Index.